SK7452001A3 - Vitronectin receptor antagonist - Google Patents

Vitronectin receptor antagonist Download PDF

Info

Publication number
SK7452001A3
SK7452001A3 SK745-2001A SK7452001A SK7452001A3 SK 7452001 A3 SK7452001 A3 SK 7452001A3 SK 7452001 A SK7452001 A SK 7452001A SK 7452001 A3 SK7452001 A3 SK 7452001A3
Authority
SK
Slovakia
Prior art keywords
receptor antagonist
vitronectin receptor
formula
compound
treatment
Prior art date
Application number
SK745-2001A
Other languages
English (en)
Slovak (sk)
Inventor
William H Miller
Peter J Manley
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of SK7452001A3 publication Critical patent/SK7452001A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
SK745-2001A 1998-12-04 1999-12-03 Vitronectin receptor antagonist SK7452001A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11090398P 1998-12-04 1998-12-04
PCT/US1999/028662 WO2000033838A1 (en) 1998-12-04 1999-12-03 Vitronectin receptor antagonist

Publications (1)

Publication Number Publication Date
SK7452001A3 true SK7452001A3 (en) 2001-12-03

Family

ID=22335565

Family Applications (1)

Application Number Title Priority Date Filing Date
SK745-2001A SK7452001A3 (en) 1998-12-04 1999-12-03 Vitronectin receptor antagonist

Country Status (39)

Country Link
US (1) US6495560B1 (bg)
EP (1) EP1146874B1 (bg)
JP (1) JP4481504B2 (bg)
KR (1) KR100620485B1 (bg)
CN (1) CN1147300C (bg)
AP (1) AP1534A (bg)
AR (1) AR035006A1 (bg)
AT (1) ATE277043T1 (bg)
AU (1) AU754408B2 (bg)
BG (1) BG65118B1 (bg)
BR (1) BR9915879A (bg)
CA (1) CA2353415A1 (bg)
CO (1) CO5150166A1 (bg)
CZ (1) CZ20011963A3 (bg)
DE (1) DE69920518T2 (bg)
DK (1) DK1146874T3 (bg)
DZ (1) DZ2954A1 (bg)
EA (1) EA003254B1 (bg)
EG (1) EG24025A (bg)
ES (1) ES2229798T3 (bg)
HK (1) HK1042037B (bg)
HU (1) HUP0104804A3 (bg)
ID (1) ID28811A (bg)
IL (2) IL143390A0 (bg)
MA (1) MA25265A1 (bg)
NO (1) NO318895B1 (bg)
NZ (1) NZ511876A (bg)
OA (1) OA11724A (bg)
PE (1) PE20001563A1 (bg)
PL (1) PL195973B1 (bg)
PT (1) PT1146874E (bg)
SI (1) SI1146874T1 (bg)
SK (1) SK7452001A3 (bg)
TR (1) TR200101654T2 (bg)
TW (1) TW482673B (bg)
UA (1) UA71586C2 (bg)
UY (1) UY25824A1 (bg)
WO (1) WO2000033838A1 (bg)
ZA (1) ZA200104398B (bg)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004525069A (ja) 2000-06-15 2004-08-19 ファルマシア・コーポレーション インテグリン受容体アンタゴニストとしてのシクロアルキルアルカン酸
ATE320258T1 (de) * 2000-10-24 2006-04-15 Merck & Co Inc Dibenzoxazepin-alpha-v-integrin- rezeptorantagonist
EP1425010B8 (en) 2001-01-29 2012-03-28 Janssen Pharmaceuticals, Inc. Substituted indoles and their use as integrin antagonists
US6872730B2 (en) * 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US20040224986A1 (en) 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
JP2006516144A (ja) 2002-12-20 2006-06-22 ファルマシア・コーポレーション インテグリン受容体アンタゴニスト誘導体としてのチアゾール化合物
GB0319069D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Therapeutically useful compounds
AR052823A1 (es) * 2004-12-21 2007-04-04 Smithkline Beecham Corp Uso de un antagonista del receptor de vitronectina para l a preparacion de una formulacion farmaceutica util para inhibir el exceso de formacion de cicatrices en la piel de a un mamifero y dicha formulacion
UA109786C2 (xx) 2010-07-14 2015-10-12 Гетероциклічні сполуки як агоністи ір-рецептора
EP2802589B1 (en) 2012-01-13 2016-01-06 Novartis AG Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
JP2016507582A (ja) 2013-02-13 2016-03-10 ノバルティス アーゲー Ｉｐ受容体アゴニスト複素環式化合物
PT3050878T (pt) 2013-09-24 2021-12-02 Fujifilm Corp Novo composto contendo azoto ou seu sal, ou seu complexo de metal

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2687154B1 (fr) 1992-02-07 1995-05-12 Rhone Poulenc Rorer Sa Nouveau derive de l'isoindolinone, sa preparation et les compositions pharmaceutiques qui le contiennent.
WO1997001540A1 (en) * 1995-06-29 1997-01-16 Smithkline Beecham Corporation Integrin receptor antagonists
WO1998013278A1 (de) * 1996-09-27 1998-04-02 Merkler, H. Tank für flüssigkeiten, insbesondere für chemisch aggressive flüssigkeiten
EP0946180A4 (en) 1996-10-07 2003-07-23 Smithkline Beecham Corp METHODS FOR STIMULATING BONE FORMATION
UY24949A1 (es) 1997-04-08 2001-04-30 Smithkline Beecham Corp Compuestos calcilíticos

Also Published As

Publication number Publication date
IL143390A0 (en) 2002-04-21
ATE277043T1 (de) 2004-10-15
NO318895B1 (no) 2005-05-18
HUP0104804A2 (hu) 2002-05-29
TR200101654T2 (tr) 2002-03-21
MA25265A1 (fr) 2001-10-01
DE69920518T2 (de) 2005-09-22
PE20001563A1 (es) 2001-02-09
EG24025A (en) 2008-03-26
OA11724A (en) 2005-01-26
KR100620485B1 (ko) 2006-09-13
HK1042037A1 (en) 2002-08-02
UA71586C2 (en) 2004-12-15
CO5150166A1 (es) 2002-04-29
BG65118B1 (bg) 2007-03-30
AU754408B2 (en) 2002-11-14
DE69920518D1 (de) 2004-10-28
EP1146874A1 (en) 2001-10-24
HK1042037B (zh) 2005-07-29
US6495560B1 (en) 2002-12-17
EA200100618A1 (ru) 2001-12-24
DK1146874T3 (da) 2005-01-31
EP1146874A4 (en) 2002-06-05
HUP0104804A3 (en) 2002-12-28
CN1147300C (zh) 2004-04-28
JP2003523931A (ja) 2003-08-12
CZ20011963A3 (cs) 2001-11-14
EP1146874B1 (en) 2004-09-22
IL143390A (en) 2006-07-05
NZ511876A (en) 2004-02-27
TW482673B (en) 2002-04-11
SI1146874T1 (en) 2005-04-30
PL348702A1 (en) 2002-06-03
JP4481504B2 (ja) 2010-06-16
AR035006A1 (es) 2004-04-14
CA2353415A1 (en) 2000-06-15
ZA200104398B (en) 2002-05-29
ID28811A (id) 2001-07-05
AU1750200A (en) 2000-06-26
DZ2954A1 (fr) 2004-06-20
CN1334730A (zh) 2002-02-06
EA003254B1 (ru) 2003-02-27
WO2000033838A1 (en) 2000-06-15
PT1146874E (pt) 2005-02-28
UY25824A1 (es) 2001-07-31
BG105651A (bg) 2002-02-28
NO20012732D0 (no) 2001-06-01
KR20010080669A (ko) 2001-08-22
AP1534A (en) 2006-01-09
ES2229798T3 (es) 2005-04-16
PL195973B1 (pl) 2007-11-30
NO20012732L (no) 2001-08-01
BR9915879A (pt) 2002-02-13

Similar Documents

Publication Publication Date Title
SK92799A3 (en) Vitronectin receptor antagonists, process for their preparation, pharmaceutical composition them containing, their use and intermediates
AU738433B2 (en) Vitronectin receptor antagonists
AU9577498A (en) Vitronectin receptor antagonist
AU9578798A (en) Vitronectin receptor antagonist
AU754408B2 (en) Vitronectin receptor antagonist
US20020019387A1 (en) Vitronectin receptor antagonist
US6576643B2 (en) Vitronectin receptor antagonists
US20020040136A1 (en) Vitronectin receptor antagonist
CZ2000979A3 (cs) Antagonista vitronektinového receptoru
MXPA00002895A (en) Vitronectin receptor antagonist
MXPA00002700A (en) Vitronectin receptor antagonists
MXPA01005547A (en) Vitronectin receptor antagonist
MXPA00002896A (en) Vitronectin receptor antagonist
CZ241599A3 (cs) Antagonista vitronektinového receptorů